ArticleFrontiers in immunology2026

FPSIR predicts clinical therapeutic responses and survival outcomes in patients with metastatic colorectal cancer undergoing first-line bevacizumab-containing chemotherapy.

Ya-Nan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.